KEGG   DRUG: Mipomersen sodiumHelp
Entry
D08946                      Drug                                   

Name
Mipomersen sodium (USAN);
Kynamro (TN)
Product
Formula
C230H305N67Na19O122P19S19
Exact mass
7589.7486
Mol weight
7594.8005
Sequence

5'-mG-mC*-mC*-mU*-mC*-dA-dG-dT-dC*-dT-dG-dC*-dT-dT-dC*-mG-mC*-mA-mC*-mC*-3'
2'-O-(2-methoxyethyl) nucleoside (m) and 2'-deoxynucleoside (d)
with  methyl  group  at  position  5 of  C  and  U  (*)
  Type
Nucleotide
Class
Cardiovascular agent
 DG01946  Hypolipidemic agent
Remark
ATC code: C10AX11
Product: D08946<US>
Efficacy
Antihyperlipidemic, Apolipoprotein B production inhibitor
  Disease
Homozygous familial hypercholesterolemia [DS:H00155]
Comment
Antisense oligonucleotide; APOB mRNA [HSA:338]
Treatment of hypercholesterolemia
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 C CARDIOVASCULAR SYSTEM
  C10 LIPID MODIFYING AGENTS
   C10A LIPID MODIFYING AGENTS, PLAIN
    C10AX Other lipid modifying agents
     C10AX11 Mipomersen
      D08946  Mipomersen sodium (USAN) <US>
USP drug classification [BR:br08302]
 Cardiovascular Agents
  Dyslipidemics, Other
   Mipomersen
    D08946  Mipomersen sodium (USAN)
Drug classes of therapeutic agents [br08360.html]
 Hypolipidemic agents
  D08946
New drug approvals in the USA [br08319.html]
 New Molecular Entity and New Therapeutic Biological Product Approvals
  D08946
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D08946
Pharmacogenomic biomarkers [br08341.html]
 Polymorphisms and germline mutations
  D08946
BRITE hierarchy
Other DBs
CAS: 629167-92-6
PubChem: 96025629
LinkDB All DBs

» Japanese version   » Back

DBGET integrated database retrieval system